Leiomyosarcoma: One disease or distinct biologic entities based on site of origin?
- 28 April 2015
- journal article
- clinical trial
- Published by Wiley in Journal of Surgical Oncology
- Vol. 111 (7) , 808-812
Abstract
Background Leiomyosarcoma (LMS) can originate from the retroperitoneum, uterus, extremity, and trunk. It is unclear whether tumors of different origin represent discrete entities. We compared clinicopathologic features and outcomes following surgical resection of LMS stratified by site of origin. Methods : Patients with LMS undergoing resection at a single institution were retrospectively reviewed. Clinicopathologic variables were compared across sites. Survival was calculated using the Kaplan–Meier method and compared using log‐rank and Cox regression analyses. Results From 1983 to 2011, 138 patients underwent surgical resection for LMS. Retroperitoneal and uterine LMS were larger, higher grade, and more commonly associated with synchronous metastases. However, disease‐specific survival, recurrence‐free survival, and recurrence patterns were not significantly different across the four sites. Synchronous metastases (HR 3.20, P < 0.001), but not site of origin, size, grade, or margin status, were independently associated with worse DSS. A significant number of recurrences and disease‐related deaths were noted beyond 5 years. Conclusions Although larger and higher grade, retroperitoneal and uterine LMS share similar survival and recurrence patterns with their trunk and extremity counterparts. LMS of various anatomic sites may not represent distinct disease processes based on clinical outcomes. The presence of metastatic disease remains the most important prognostic factor for LMS. J. Surg. Oncol. 2015 111:808–812.Keywords
This publication has 23 references indexed in Scilit:
- The Influence of Primary Site on Outcomes in LeiomyosarcomaAmerican Journal of Clinical Oncology, 2013
- Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE projectEuropean Journal of Cancer, 2013
- Predictors of Survival and Recurrence in Primary LeiomyosarcomaAnnals of Surgical Oncology, 2013
- Management of Soft Tissue Sarcoma2013
- Soft tissue sarcoma across the age spectrum: A population‐based study from the surveillance epidemiology and end results databasePediatric Blood & Cancer, 2011
- Gastrointestinal stromal tumors and leiomyosarcomasJournal of Surgical Oncology, 2008
- Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma GroupCancer, 2007
- Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 casesInternational Journal of Cancer, 2006
- Evaluation of biological potential of smooth muscle tumoursHistopathology, 2005
- Clinicopathological prognostic factors in soft tissue leiomyosarcoma: a multivariate analysisHistopathology, 2002